ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0137

PROMIS-29 Scores Are Significantly Higher in Patients with Rheumatoid Arthritis Who Meet Criteria for Co-morbid Fibromyalgia (FM) Than in Those with Rheumatoid Arthritis and No FM

Kathryn Gibson1, Geraldine Hassett2 and Theodore Pincus3, 1Liverpool Hospital, Sydney, Australia, 2Liverpool Hospital, Sydney, Liverpool BC, NSW, New South Wales, Australia, 3Rush University Medical Center, Chicago, IL

Meeting: ACR Convergence 2020

Keywords: fibromyalgia, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The Patient-Reported Outcomes Measurement Information System short form 29 (PROMIS-29)1 uses computer assisted technology (CAT) to derive patient assessments.  High PROMIS-29 scores are seen in patients with rheumatoid arthritis (RA) with high disease activity, but may also reflect co-morbid FM. This problem is seen also in traditional indices used to assess patients with rheumatoid arthritis (RA), including DAS28, CDAI, and RAPID3 (routine assessment of patient index data 3). For example, a patient with no tender or swollen joints, a physician global assessment of 0, ESR of 20 mm/hr, but a patient global assessment of 80/100, would have a DAS28 of 3.2, suggesting moderate disease activity. Therefore, high scores may indicate high disease activity or co-morbid FM (or both) in RA patients.

Methods: All RA patients attending the Rheumatology clinic at Liverpool Hospital complete a MDHAQ at each visit, and were asked to complete a PROMIS-29 questionnaire,1 and the 2011 modification of the criteria for Fibromyalgia (2011 FM criteria)3 on paper.  Two indices derived from MDHAQ scores RAPID3=0-30: (physical function=0-10 + pain=0-10 + patient global assessment=0-10) assesses clinical status, and FAST3-P (Fibromyalgia Assessment Screening Tool 3 (2/3=FM): pain≥6/10=1 + number of painful joints≥16/48=1 + number of symptoms≥16/60=1) provides a clue to the presence of FM. PROMIS-29 t-scores were obtained from the Assessment Center scoring service (https://www.assessmentcenter.net/ac_scoringservice). Cross sectional analysis of 159 patients with complete data was performed. Descriptive statistics and t-tests were derived using Stata/IC 16.1 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.)

Results: Patients had a mean (SD) age of 55.7 (15.2) years, were 67.3% female and had a mean education of 11.6 (4.0) years. 23.3% were found to have co-morbid FM by 2011 FM criteria and 28.9% by FAST3-P criteria. All PROMIS-29 t-scores indicated significantly poorer status in patients with co-morbid FM either by 2011 FM criteria or by FAST3-P criteria (Table). All scores for pain interference, depression/sadness, fatigue, anxiety/fear and sleep disturbance and poorer physical function and ability to participate were more than 0.5 SD from the population mean in the FM positive group, and within 0.5 SD of the population mean in those who did not have positive screening for FM (Table). All MDHAQ variables, including the components of RAPID3 indicated significantly poorer status in patients with co-morbid FM by either criterion (data not shown).

Conclusion: RA patients with comorbid FM by either the 2011 FM criteria or by FAST3-P had significantly higher PROMIS-29 t-scores, than RA patients who did not have FM. Interpretation of these scores in RA patients should consider whether there is coexisting FM in addition to any active inflammatory disease.

  1. Cella D.et al (2019) Value in Health, 22(5):537-544.
  2. Pincus T et al (2007) Best Pract Res Clin Rheumatol; 21(4):789– 804.
  3. Wolfe F et al. (2011) J Rheumatol; 38:1113-22.

PROMIS29 and RAPID3 in all patients and patients with and without FM by 2011 and FAST3P criteria. Higher scores indicate more of the concept being measured in PROMIS-29. In MDHAQ higher scores indicate more severe patient impact of the concept being measured.


Disclosure: K. Gibson, Janssen, 1, UCB, 1, Novartis, 1, Abbvie, 1; G. Hassett, Abbvie, 1, Amgen, 1, Janssen, 1; T. Pincus, Medical History Services LLC, 9.

To cite this abstract in AMA style:

Gibson K, Hassett G, Pincus T. PROMIS-29 Scores Are Significantly Higher in Patients with Rheumatoid Arthritis Who Meet Criteria for Co-morbid Fibromyalgia (FM) Than in Those with Rheumatoid Arthritis and No FM [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/promis-29-scores-are-significantly-higher-in-patients-with-rheumatoid-arthritis-who-meet-criteria-for-co-morbid-fibromyalgia-fm-than-in-those-with-rheumatoid-arthritis-and-no-fm/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/promis-29-scores-are-significantly-higher-in-patients-with-rheumatoid-arthritis-who-meet-criteria-for-co-morbid-fibromyalgia-fm-than-in-those-with-rheumatoid-arthritis-and-no-fm/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology